Deconstructing the evolution of metastasis

Acronym

Evomet

Description of the granted funding

Evomet aims to create a high-level training programme on the various aspects of metastasis evolution in order to provide young researchers with skills to become future leaders in the field. To this end, it is imperative to have a solid mentoring and training strategy, a state-of-the-art scientific approach, and a broad range of complementary soft skills. Collectively, these skills will be provided to each ESR through a series of events (local and network-wide) and initiatives that will allow ESRs to ensure smooth progress of their research projects and a successful career. Scientifically, Evomet has been designed to address an unmet medical need through leverage of basic science to impact drug development and, ultimately, improve how patients are managed. Scientific WPs tackling metastasis from a functional perspective have been defined. To metastasize, cancer cells must orchestrate diverse cellular functions to overcome the challenges inherent in the metastatic cascade (Cell Fate – WP1). These functions are also highly dependent on the interactions of the metastatic cell with the host immune system and tissue stroma (Environment – WP2). However, the kinetics of metastasis and, in particular, the mechanisms that regulate metastasis latency remain poorly understood (Latency – WP3). Mapping this complexity, examining patterns of clonal evolution, mechanisms of therapy failure, and pathways for expansion is central to defining new targets (Expansion – WP4). In summary, we are facing a fast-growing multidisciplinary area created from the aggregation of different fields that have problems communicating with each other. Evomet’s success builds on the strong relations between partners, the open exchange of ideas, state-of-the-art methodology, tools and equipment as well as the exploitation of synergistic opportunities between the network members, covering different perspectives and filling the gap between them, thus breaking the isolation between disciplines.
Show more

Starting year

2021

End year

2025

Granted funding

280 805.76 €
Participant
UNIVERSITE PARIS-SACLAY (FR)
274 802.04 €
Participant
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS (ES)
501 809.76 €
Participant
BOEHRINGER INGELHEIM RCV GMBH & CO KG (AT)
264 207.24 €
Participant
INTOMICS AS (DK)
297 522 €
Participant
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (UK)
303 172.56 €
Participant
FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA (ES)
250 904.88 €
Participant
FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES)
501 809.76 €
Coordinator
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (ES)
250 904.88 €
Participant
UNIVERSITE DE LAUSANNE (CH)
281 276.64 €
Participant
UNIVERSITAT BASEL (CH)
281 276.64 €
Participant
FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH (AT)
264 207.24 €
Participant
UNIVERSITE LIBRE DE BRUXELLES (BE)
455 680 €
Participant

Amount granted

4 014 435 €

Funder

European Union

Funding instrument

Marie Skłodowska-Curie Innovative Training Networks (ITN)

Framework programme

Horizon 2020 Framework Programme

Call

Programme part
EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (5220)
Fostering new skills by means of excellent initial training of researchers (5221)
Topic
Innovative Training Networks (MSCA-ITN-2020)
Call ID
H2020-MSCA-ITN-2020

Other information

Funding decision number

955951

Identified topics

bioinformatics